Technology
Our Facility
Starton’s Development Facility, located in Paramus NJ, drives activities such as formulation development, analytical and preclinical testing, and clinical trial material production to support GMP Phase 1 clinical trials.
Our drug delivery platform technology provides a controlled, sustained release over multiple days.
The use of continuous delivery allows for lower peaks and higher troughs which provide therapeutic blood levels for the entirety of the dosing interval whereas once-daily oral dosing is associated with sub-therapeutic blood levels during each day’s dosing. Importantly, the total daily exposure can be 55-70% lower than once-daily oral administration with a resultant AUC similarly lower than oral therapy. The expected result of this “flattening of the curve” of blood levels is better tolerability through lower exposure and improved efficacy through continuous maintenance of the minimum immunomodulatory concentration of the treatment interval.
traditional delivery vs continuous delivery
Short half-life drugs wear off quickly and leave cancer cells to recover or create resistance between dosing intervals
Short half-life drugs require a high initial dose, resulting in high blood levels potentially leading to adverse reactions
Starton uses continuous delivery systems to improve outcomes and quality of life
Starsilon and Starticles
The STARSILON and STARTICLES platform technologies will enable the transdermal delivery of challenging APIs not previously considered viable candidates for the transdermal route of administration.
Our novel and proprietary technology for drug-in-adhesive transdermal delivery systems, STARSILON, potentially expands the number of active pharmaceutical ingredients (APIs) that can be delivered transdermally by addressing their challenging characteristics.
A typical solubilized drug-in-adhesive technology is most commonly employed for transdermal patches which has been found to have limited applicability for difficult to work with APIs. STARSILON has demonstrated improvement in availability, permeability, and stability of several APIs when compared to standard drug-in-adhesive platforms.
This technology potentially offers viable alternatives to the typical solubilized drug-in-adhesive transdermal platform and enables us to pursue our goals to achieve continuous and low-dose delivery of various molecules, such as those in use for oncology, inflammation, and CNS activities with the potential for significant improvement in efficacy, reduction in toxicity, and improved tolerance. In addition, STARSILON can potentially reduce the size of transdermal patches and expand the period of release.
This platform, which is complementary to STARSILON, is Starton Therapeutic’s proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch in the form of a molecular solid suspension for delivery of active pharmaceutical ingredients (API).
STARTICLES is a variation of traditional transdermal systems to overcome high melting points and low solubility to improve the availability of the API for achieving higher permeation rates through the skin.
This unique and proprietary technology enables the incorporation of APIs within the Food and Drug Administration’s Biopharmaceuticals Classification System (BCS), specifically those of BCS Class II (high permeability and low solubility) and BCS Class IV (low permeability and low solubility). The ability to deliver these classes of compounds transdermally is expected to overcome common deficiencies of other dosage forms, such as traditional solubilized drug-in-adhesive, oral, or IV bolus administration. Such dosage forms have demonstrated issues with drug loading, dose delivery limitations, or toxicity, as well as inconsistent pharmacokinetic profiles that are often encountered after administration.